Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis.

Tytuł:: Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis.
Autorzy:: Miyagawa H; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hara H; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Araya J; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Minagawa S; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Numata T; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Umezawa Y; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Asahina A; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Nakagawa H; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Kuwano K; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Źródło:: PloS one [PLoS One] 2021 Jan 07; Vol. 16 (1), pp. e0245284. Date of Electronic Publication: 2021 Jan 07 (Print Publication: 2021).
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:: Biological Products/*adverse effects
Dermatologic Agents/*adverse effects
Immunosuppressive Agents/*adverse effects
Interleukin-17/*antagonists & inhibitors
Interleukin-23/*antagonists & inhibitors
Lung Diseases, Interstitial/*etiology
Psoriasis/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Biological Products/therapeutic use ; Dermatologic Agents/therapeutic use ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Lung Diseases, Interstitial/pathology ; Male ; Middle Aged
References:: J Dermatolog Treat. 2020 Apr 2;:1-15. (PMID: 32202445)
Acta Derm Venereol. 2019 Mar 1;99(3):331-332. (PMID: 30426134)
Br J Dermatol. 2019 Mar;180(3):684-685. (PMID: 30430554)
Respir Med. 2018 Jan;134:6-11. (PMID: 29413509)
Am J Respir Crit Care Med. 2002 Feb 1;165(3):378-81. (PMID: 11818324)
Chest. 1989 Jul;96(1):68-73. (PMID: 2661160)
J Dermatol. 2020 Mar;47(3):201-222. (PMID: 31916326)
Clin Exp Dermatol. 2016 Jan;41(1):88-90. (PMID: 25557847)
Respir Res. 2012 May 31;13:39. (PMID: 22651223)
Expert Rev Clin Immunol. 2017 Jun;13(6):525-534. (PMID: 28165883)
J Dermatol. 2016 Jun;43(6):712-3. (PMID: 26703791)
Hautarzt. 2020 Apr;71(4):309-312. (PMID: 31792580)
J Clin Med. 2018 Oct 15;7(10):. (PMID: 30326612)
Ann Rheum Dis. 2008 Feb;67(2):189-94. (PMID: 17644554)
J Invest Dermatol. 2013 Jan;133(1):17-26. (PMID: 22673731)
J Dermatol. 2017 Dec;44(12):e322-e323. (PMID: 28771789)
JAMA Dermatol. 2019 Feb 1;155(2):221-224. (PMID: 30540343)
Respir Res. 2011 Jul 26;12:97. (PMID: 21791074)
Respiration. 2004 Jul-Aug;71(4):301-26. (PMID: 15316202)
J Allergy Clin Immunol. 2001 Oct;108(4):475-88. (PMID: 11590368)
Immunity. 2019 Apr 16;50(4):892-906. (PMID: 30995505)
Respir Investig. 2013 Dec;51(4):260-77. (PMID: 24238235)
Mayo Clin Proc Innov Qual Outcomes. 2018 Sep 20;2(4):370-377. (PMID: 30560239)
Front Immunol. 2018 Aug 02;9:1682. (PMID: 30127781)
J Med Dent Sci. 2003 Sep;50(3):213-24. (PMID: 15074359)
Nat Rev Dis Primers. 2016 Nov 24;2:16082. (PMID: 27883001)
Substance Nomenclature:: 0 (Antibodies, Monoclonal, Humanized)
0 (Biological Products)
0 (Dermatologic Agents)
0 (Immunosuppressive Agents)
0 (Interleukin-17)
0 (Interleukin-23)
6ZA31Y954Z (brodalumab)
BTY153760O (ixekizumab)
DLG4EML025 (secukinumab)
Entry Date(s):: Date Created: 20210107 Date Completed: 20210513 Latest Revision: 20210513
Update Code:: 20240105
PubMed Central ID:: PMC7790374
DOI:: 10.1371/journal.pone.0245284
PMID:: 33411857
: Czasopismo naukowe

Pełny tekst

Objectives: Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.
Methods: We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23 biologics. Chest CT was performed to evaluate DIIP. Serum KL-6 levels were measured before treatment (baseline) and during treatment.
Results: A total of 603 psoriasis patients were treated with anti-IL-17/23 biologics with mean follow-up of 21.1 months. Six patients developed DIIP at mean 14 months after initiation of the therapy. Older age, higher baseline KL-6 value and more frequent pre-existing IPs were associated with development of DIIP by univariate analysis. At the onset of DIIP, elevated serum KL-6 levels with concomitantly increased ground glass opacity (GGO) in Chest CT were demonstrated. DIIP was improved by only cessation of causative agents in five patients but steroid therapy was needed in one patient.
Conclusions: DIIP is a plausible complication of anti-IL-17/23 biologics. Age, baseline KL-6 level and underlying IP could be the risk factors for DIIP development. Serum KL-6 levels and chest CT are useful for not only predicting but also detecting DIIP caused by anti-IL-17/23 biologics.
Competing Interests: The authors have declared that no competing interests exist.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja